Novartis Ag

Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Array Biopharma Inc.

Scott Delach

Ping Zhu

Levi A Garraway

Giordano Caponigro

Sunkyu Kim

Darrin Stuart

Wenlai Zhou

Vesselina Cooke

Shivang Doshi

Manav Korpal

Thomas Horn-Spirohn

Joshua Korn

Zainab Jagani

Alice Loo

Gregory Kryukov

Compositions and methods are provided for diagnosis, prognosis and treatment of AR-related diseases, such as prostate diseases, such as prostate cancer, breast cancer, and many other diseases. In particular, a novel and clinically relevant mutation at position 877 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and therapeutic regimens can be planned on the basis of the presence or absence of this mutation. Polypeptides comprising, antibodies to, and polynucleotides encoding the mutant AR can be used to identity novel treatments. A double mutation in AR at positions 742 and 878 is also shown to be useful for patient stratification.

Androgen receptor mutation

A combination of a CDK4/6 inhibitor and a MEK inhibitor for the treatment of diseases such as cancer.

Pharmaceutical combination comprising binimetinib

A pharmaceutical combination comprising (a) CDK4/6 inhibitor (b) a B-Raf inhibitor, and optionally (c) a MEK 1/2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Pharmaceutical combinations of a CDK4/6 inhibitor and a B-RAF inhibitor

Growing community of inventors

Cambridge, MA, United States of America

Scott Delach